BioSpace News Archive

Cognito Therapeutics , announced today that its proprietary gamma sensory stimulation at 40Hz over a 6-month period reduced white matter atrophy in the brain for patients with Alzheimer’s Disease, according to new data presented at the Alzheimer’s Association International Conference 2022.

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser surgical solutions for the treatment of cataracts, today announced that the Company’s second quarter 2022 financial results will be released before market open on Monday, August 8, 2022.

Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, today announced that its President and Chief Executive Officer, Markus Renschler, MD, will participate in the 2022 Wedbush PacGrow Healthcare Virtual Conference on August 9, 2022.

Agenus Inc. today announced that the first patient has been dosed in the Phase 1 study of AGEN1571 in advanced solid tumors.

Surgalign Holdings, Inc., a global medical technology company focused on elevating the standard of care by driving the evolution of digital health, announced its plans to release financial results for its second quarter ended June 30, 2022 after the close of trading on August 9, 2022.

Evofem Biosciences, Inc., (Nasdaq: EVFM) today announced that the last subject has completed her last visit in EVOGUARD, the Company’s registrational Phase 3 trial evaluating the efficacy and safety of Phexxi® (lactic acid, citric acid, potassium bitartrate) for the prevention of chlamydia and gonorrhea infection in women.

G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Company will participate in two upcoming virtual investor conferences in August 2022.

BIOXYTRAN, INC. (Symbol: BIXT) (the “Company”), announced today that the journal of International Journal of Health Sciences1 released a peer-reviewed article, “Carbohydrate ProLectin-M, a Galectin-3 Antagonist, Blocks SARS-CoV-2 Activity”, that supports ProLectin-M’s in vitro Mode of Action and the initial clinical data results reported in a previous article, referred to below.

Brand Institute, the global leader in pharmaceutical and healthcare-related name development, is pleased to share the Name Review Group meeting dates and respective submission deadlines, as announced by the European Medicines Agency.

Digital dentistry, including CAD/CAM dentistry, is transforming every aspect of professional oral care in dentistry to date.